Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15094149 | 0.83 | RAB9A (0.43) | RAB9AMRGPRX4MAPK1SMN1; SMN2SCN9A | |
| SCHEMBL15670289 | 0.81 | SMN1; SMN2 (0.37) | RAB9AMRGPRX4SMN1; SMN2EPHX2CDK1 | |
| SCHEMBL15350290 | 0.79 | MRGPRX4 (0.47) | MRGPRX4SMN1; SMN2EPHX2SCN9A | |
| SCHEMBL15350633 | 0.78 | EPHX2 (0.41) | MRGPRX4MAPK1SMN1; SMN2EPHX2SCN9A | |
| SCHEMBL15094325 | 0.77 | RAB9A (0.42) | RAB9AMRGPRX4MAPK1SMN1; SMN2SCN9A | |
| SCHEMBL16175019 | 0.77 | RAB9A (0.39) | RAB9AMRGPRX4MAPK1SMN1; SMN2SCN9A | |
| SCHEMBL15358624 | 0.77 | EPHX2 (0.36) | MRGPRX4SMN1; SMN2EPHX2CDK1CDK2 | |
| SCHEMBL28012429 | 0.76 | EPHX2 (0.40) | MRGPRX4SMN1; SMN2EPHX2SCN9ALMNA | |
| SCHEMBL363857 | 0.75 | SCN9A (0.49) | RAB9AMRGPRX4MAPK1SMN1; SMN2SCN9A | |
| SCHEMBL16177396 | 0.74 | RORC (0.41) | RAB9AMRGPRX4MAPK1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102621-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| EP-2593431-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-19 | — | — | EP | disclosed |
| EP-2593432-B1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LTD (GB) | 2014-10-22 | — | — | EP | disclosed |
| US-8592629-B2 | Sulfonamide derivatives as Nav 1.7 inhibitors | PFIZER LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| EP-2593432-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| EP-2593431-A2 | CHEMICAL COMPOUNDS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| US-20130109708-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2012007861-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007869-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109708-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | RAB9A 1215/4885MRGPRX4 761/4885MAPK1 222/4885 |
| US-20120010183-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | RAB9A 1252/4885MRGPRX4 342/4885MAPK1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.